How big is the Radiotheranostics Market | Key Insights & Opportunities 2025

How big is the radiotheranostics market?

The market growth is driven by the increasing prevalence of cancer, rising adoption of precision medicine, growing R&D in nuclear medicine, and regulatory approvals of novel radiotheranostic agents.

Key Growth Drivers of the Radiotheranostics Market

• Rising global cancer burden requiring advanced targeted therapies
• Expanding adoption of personalized and precision medicine approaches
• Increased availability of nuclear medicine infrastructure and isotopes
• Growing clinical trials and approvals of radiotheranostic drugs
• Supportive healthcare policies and funding in oncology care

Radiotheranostics Market Trends

The radiotheranostics market is experiencing trends such as integration of imaging and therapy for improved patient outcomes, rising collaborations between pharma and nuclear medicine companies, and advancements in PET/CT-based theranostic platforms. Alpha- and beta-emitting isotopes are in growing demand as is development of expanding indications outside of oncology, into cardiovascular and neurological applications.

Emerging Developments in the Radiotheranostics Market

Radiotheranostics market is currently experiencing trends such as faster FDA and EMA approvals of innovative radiopharmaceuticals, alliances between research centres and biotechnology companies, and the introduction of new generation radiopharmaceuticals Actinium-225. Moreover, the production facilities of theranostics and the development of targeted drugs in rare cancers are transforming the industry.

List of Leading Companies in the Radiotheranostics Market

Below is a comprehensive list of the leading market players driving growth in this sector:

1. Novartis AG (Advanced Accelerator Applications & Endocyte)

Novartis leads radiotheranostics with Lutathera (Lu-177 DOTATATE) and Pluvicto (Lu-177 vipivotide tetraxetan), pairing targeted diagnostics with radionuclide therapy in NETs and prostate cancer.

2. Lantheus Holdings, Inc. (incl. Progenics)

Lantheus provides PET diagnostics like Pylarify® (F-18 PSMA) and develops therapeutic PSMA programs, enabling prostate cancer theranostic pathways from imaging to treatment.

3. Telix Pharmaceuticals Limited

Telix commercializes Illuccix (Ga-68 PSMA-11) and advances kidney, brain, and hematology programs, building integrated PSMA and beyond-PSMA theranostic portfolios.

4. Curium Pharma

Curium operates a global radio pharmacy and isotope network, supplying PET/SPECT diagnostics and developing targeted radiopharmaceutical therapies for oncology.

5. ITM Isotope Technologies Munich SE

ITM is a leader in high-purity no-carrier-added Lu-177 supply and targeted radiopharmaceutical development, enabling precision therapy–diagnostic pairings in cancer.

6. Eckert & Ziegler Strahlen- und Medizintechnik AG

Eckert & Ziegler supplies medical radioisotopes (incl. Ge-68/Ga-68 generators and Lu-177) and contract manufacturing, underpinning global radiotheranostic supply chains.

7. Bayer AG

Bayer markets Xofigo® (Ra-223) for metastatic prostate cancer and is expanding a pipeline of targeted alpha therapies to complement diagnostic PET imaging agents.

8. Bracco Imaging S.p.A. / Blue Earth Diagnostics

Blue Earth (a Bracco company) offers Poslumaâ„¢ / PYLARIFY AI-compatible F-18 rhPSMA imaging and develops next-gen tracers to support PSMA theranostic workflows.

9. Cardinal Health Nuclear & Precision Health Solutions

Cardinal Health runs one of the largest radio pharmacy networks, providing last-mile distribution, dose compounding, and logistics for PET/SPECT diagnostics and therapy.

10. GE HealthCare Technologies Inc.

GE HealthCare supplies PET/CT and SPECT/CT scanners, cyclotrons, and radiochemistry systems, enabling end-to-end radiotheranostic imaging, production, and workflow solutions.

How big is the Radiotheranostics Market : FAQ's